IBI115: IBI115 will be administered. The Dose Limiting Toxicity (DLT) observation period will last for 28 or 21 days after first dose. After completion of the DLT observation period, subject will continue to receive IBI115 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal od consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.
Study summary
This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria：
1. Participants must be able to understand and sign the written informed consent form for participation in this trial, including all evaluations and procedures specified in this protocol.
2. Male or female participants aged ≥18 years and ≤75 years.
3. Participants with histologically or cytologically confirmed advanced small cell lung cancer.
4. At least one measurable lesion according to RECIST V1.1 within 28 days prior to the first dose of IBI115.
5. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.
6. Expected survival period ≥12 weeks.
7. Adequate bone marrow and organ function confirmed during the screening period.
Exclusion Criteria：
1. Concurrent participation in another interventional clinical study, except for observational non-interventional studies or being in the survival follow-up phase of an interventional study.
2. Administration of a live vaccine within 4 weeks prior to the first dose of the study drug or a cancer vaccine within 3 months prior, or planning to receive any live vaccine during the study period.
3. Adverse reactions from prior anti-tumor therapy that have not resolved to CTCAE v6.0 Grade 0, Grade 1, or baseline levels by the time of the first dose of the study drug.
4. Known hypersensitivity or intolerance to IBI115, sintilimab, or any of their excipients.
Primary outcome measure(s)
Number of participants with Adverse Events (AE), Serious Adverse Events (SAE) and treatment emergent adverse events (TEAE) — up to 90 days after the last administration Safety Features including Adverse Events (AE), Serious Adverse Events (SAE) and treatment emergent adverse events (TEAE).
Dose-limiting toxicity (DLT) — up to 28 days after the first dose of IBI115 DLTs will be assessed during the DLT observation period to determine maximum tolerated dose (MTD) ) and/or recommended dose for combination (RDC).
MTD of IBI115 — up to 90 days after the last administration to determine MTD of IBI115
RDC of IBI115 — up to 90 days after the last administration to determine RDC of IBI115
Number of participants with clinically significant changes in physical examination results — up to 90 days after the last administration A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.
Number of participants with abnormal vital signs — up to 90 days after the last administration Collection of vital signs will include body temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation.
Trial sites (1)
Facility
City
Region
Status
the second affiliated hospital of AMU
Chongqing
Chongqing Municipality
Recruiting
More Innovent Biologics (Suzhou) Co. Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.